Loading…
The effects of ipragliflozin on the liver-to-spleen attenuation ratio as assessed by computed tomography and on alanine transaminase levels in Japanese patients with type 2 diabetes mellitus
We assessed the effects of a 12-week ipragliflozin treatment on the liver-to-spleen attenuation ratio ( L / S ratio) using computed tomography and on alanine transaminase (ALT) levels in Japanese patients with type 2 diabetes mellitus (T2DM). Sixty-two patients with T2DM [age, 56 ± 8 years; hemoglob...
Saved in:
| Published in: | Diabetology international 2017-06, Vol.8 (2), p.218-227 |
|---|---|
| Main Authors: | , , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c595t-3e6061572c1a8e1492bf14d8e8f651a5e0b6759c2c26fbe18d92a7c608629e8f3 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c595t-3e6061572c1a8e1492bf14d8e8f651a5e0b6759c2c26fbe18d92a7c608629e8f3 |
| container_end_page | 227 |
| container_issue | 2 |
| container_start_page | 218 |
| container_title | Diabetology international |
| container_volume | 8 |
| creator | Bando, Yukihiro Ogawa, Ayumi Ishikura, Kazuhide Kanehara, Hideo Hisada, Azusa Notumata, Kazuo Okafuji, Kazuhiro Toya, Daisyu |
| description | We assessed the effects of a 12-week ipragliflozin treatment on the liver-to-spleen attenuation ratio (
L
/
S
ratio) using computed tomography and on alanine transaminase (ALT) levels in Japanese patients with type 2 diabetes mellitus (T2DM). Sixty-two patients with T2DM [age, 56 ± 8 years; hemoglobin A1c (HbA1c) levels, 8.1 ± 0.9%; body mass index (BMI), 27.5 ± 3.3 kg/m
2
] were randomly assigned in a 2:1 ratio to receive ipragliflozin (50 mg/day; ipragliflozin group;
n
= 40) or continued treatment (control group;
n
= 22) for 12 weeks. The primary endpoints were changes in ALT levels; the secondary endpoints included changes in the
L
/
S
ratio and in the visceral fat area (VFA) and subcutaneous fat area (SFA) before and after 12 weeks of the treatment as assessed by computed tomography. ALT levels (−12.45 vs. +5.82 IU/l,
P
|
| doi_str_mv | 10.1007/s13340-016-0302-y |
| format | article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6224952</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2163014903</sourcerecordid><originalsourceid>FETCH-LOGICAL-c595t-3e6061572c1a8e1492bf14d8e8f651a5e0b6759c2c26fbe18d92a7c608629e8f3</originalsourceid><addsrcrecordid>eNp1Uk2L3DAMDaWlu0z3B_RSDL30ktZ2Jk5yKZSlnyz0sj0bxVFmvDh2ajtT0h_X31YNsx22hRqBhPX0JKFXFM8Ffy04b94kUVVbXnKhSl5xWa6PikspOl4K1arH57hpL4qrlO44vW0neKOeFhcVV7yqZH1Z_LrdI8NxRJMTCyOzc4Sds6MLP61nwbNMeWcPGMscyjQ7RM8gZ_QLZEv5eHQMEllCsoH1KzNhmpdMcQ5T2EWY9ysDPxz5wIG3HlmO4BNM1kOiBnhAlxh1_AIzeKSvmXjR01A_bN6zvM7IJBss9JgxsQmds3lJz4onI7iEV_d-U3z78P72-lN58_Xj5-t3N6WpuzqXFSquRN1II6BFse1kP4rt0GI7qlpAjbxXTd0ZaaQaexTt0ElojOKtkh2Bqk3x9sQ7L_2Eg6HJIjg9RztBXHUAq__OeLvXu3DQSsptV0sieHVPEMP3BVPWk02GtqBtw5K0FKriNBidZVO8_Ad6F5boaT1NJxWN6mrBCSVOKBNDShHH8zCC66NA9EkgmgSijwLRK9W8eLjFueKPHAggT4BEKb_D-KD1f1l_A6cny3U</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1901769510</pqid></control><display><type>article</type><title>The effects of ipragliflozin on the liver-to-spleen attenuation ratio as assessed by computed tomography and on alanine transaminase levels in Japanese patients with type 2 diabetes mellitus</title><source>PubMed (Medline)</source><source>Springer Nature</source><creator>Bando, Yukihiro ; Ogawa, Ayumi ; Ishikura, Kazuhide ; Kanehara, Hideo ; Hisada, Azusa ; Notumata, Kazuo ; Okafuji, Kazuhiro ; Toya, Daisyu</creator><creatorcontrib>Bando, Yukihiro ; Ogawa, Ayumi ; Ishikura, Kazuhide ; Kanehara, Hideo ; Hisada, Azusa ; Notumata, Kazuo ; Okafuji, Kazuhiro ; Toya, Daisyu</creatorcontrib><description><![CDATA[We assessed the effects of a 12-week ipragliflozin treatment on the liver-to-spleen attenuation ratio (
L
/
S
ratio) using computed tomography and on alanine transaminase (ALT) levels in Japanese patients with type 2 diabetes mellitus (T2DM). Sixty-two patients with T2DM [age, 56 ± 8 years; hemoglobin A1c (HbA1c) levels, 8.1 ± 0.9%; body mass index (BMI), 27.5 ± 3.3 kg/m
2
] were randomly assigned in a 2:1 ratio to receive ipragliflozin (50 mg/day; ipragliflozin group;
n
= 40) or continued treatment (control group;
n
= 22) for 12 weeks. The primary endpoints were changes in ALT levels; the secondary endpoints included changes in the
L
/
S
ratio and in the visceral fat area (VFA) and subcutaneous fat area (SFA) before and after 12 weeks of the treatment as assessed by computed tomography. ALT levels (−12.45 vs. +5.82 IU/l,
P
< 0.001),
L
/
S
ratio (+0.07 vs. −0.08,
P
< 0.001), SFA (−5.8 vs. +13.3 cm
2
,
P
< 0.05), and VFA (+1.4 vs. +20.4 cm
2
,
P
< 0.05) significantly changed from baseline in the ipragliflozin group compared with the values in the control group. Multiple regression analysis among all subjects revealed that the independent factor contributing to the %ΔALT and %Δ
L
/
C
ratio was treatment group alone (ipragliflozin group = 1; control group = 0;
β
coefficient = −32.08,
P
< 0.001 and
β
coefficient = 19.98,
P
< 0.05, respectively). Thus, ipragliflozin may lower ALT levels associated with increased
L
/
S
ratios, indicating its potential therapeutic efficacy in T2DM-associated hepatic steatosis.]]></description><identifier>ISSN: 2190-1678</identifier><identifier>EISSN: 2190-1686</identifier><identifier>DOI: 10.1007/s13340-016-0302-y</identifier><identifier>PMID: 30603325</identifier><language>eng</language><publisher>Tokyo: Springer Japan</publisher><subject>Age ; Alanine ; Alanine transaminase ; Body mass ; Body mass index ; Computed tomography ; Diabetes ; Diabetes mellitus ; Endocrinology ; Fatty liver ; Hemoglobin ; Liver ; Medicine ; Medicine & Public Health ; Metabolic Diseases ; Multiple regression analysis ; Original ; Original Article ; Spleen ; Steatosis ; Tomography ; Transaminase</subject><ispartof>Diabetology international, 2017-06, Vol.8 (2), p.218-227</ispartof><rights>The Japan Diabetes Society 2016</rights><rights>Copyright Springer Science & Business Media 2017</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c595t-3e6061572c1a8e1492bf14d8e8f651a5e0b6759c2c26fbe18d92a7c608629e8f3</citedby><cites>FETCH-LOGICAL-c595t-3e6061572c1a8e1492bf14d8e8f651a5e0b6759c2c26fbe18d92a7c608629e8f3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6224952/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6224952/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30603325$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Bando, Yukihiro</creatorcontrib><creatorcontrib>Ogawa, Ayumi</creatorcontrib><creatorcontrib>Ishikura, Kazuhide</creatorcontrib><creatorcontrib>Kanehara, Hideo</creatorcontrib><creatorcontrib>Hisada, Azusa</creatorcontrib><creatorcontrib>Notumata, Kazuo</creatorcontrib><creatorcontrib>Okafuji, Kazuhiro</creatorcontrib><creatorcontrib>Toya, Daisyu</creatorcontrib><title>The effects of ipragliflozin on the liver-to-spleen attenuation ratio as assessed by computed tomography and on alanine transaminase levels in Japanese patients with type 2 diabetes mellitus</title><title>Diabetology international</title><addtitle>Diabetol Int</addtitle><addtitle>Diabetol Int</addtitle><description><![CDATA[We assessed the effects of a 12-week ipragliflozin treatment on the liver-to-spleen attenuation ratio (
L
/
S
ratio) using computed tomography and on alanine transaminase (ALT) levels in Japanese patients with type 2 diabetes mellitus (T2DM). Sixty-two patients with T2DM [age, 56 ± 8 years; hemoglobin A1c (HbA1c) levels, 8.1 ± 0.9%; body mass index (BMI), 27.5 ± 3.3 kg/m
2
] were randomly assigned in a 2:1 ratio to receive ipragliflozin (50 mg/day; ipragliflozin group;
n
= 40) or continued treatment (control group;
n
= 22) for 12 weeks. The primary endpoints were changes in ALT levels; the secondary endpoints included changes in the
L
/
S
ratio and in the visceral fat area (VFA) and subcutaneous fat area (SFA) before and after 12 weeks of the treatment as assessed by computed tomography. ALT levels (−12.45 vs. +5.82 IU/l,
P
< 0.001),
L
/
S
ratio (+0.07 vs. −0.08,
P
< 0.001), SFA (−5.8 vs. +13.3 cm
2
,
P
< 0.05), and VFA (+1.4 vs. +20.4 cm
2
,
P
< 0.05) significantly changed from baseline in the ipragliflozin group compared with the values in the control group. Multiple regression analysis among all subjects revealed that the independent factor contributing to the %ΔALT and %Δ
L
/
C
ratio was treatment group alone (ipragliflozin group = 1; control group = 0;
β
coefficient = −32.08,
P
< 0.001 and
β
coefficient = 19.98,
P
< 0.05, respectively). Thus, ipragliflozin may lower ALT levels associated with increased
L
/
S
ratios, indicating its potential therapeutic efficacy in T2DM-associated hepatic steatosis.]]></description><subject>Age</subject><subject>Alanine</subject><subject>Alanine transaminase</subject><subject>Body mass</subject><subject>Body mass index</subject><subject>Computed tomography</subject><subject>Diabetes</subject><subject>Diabetes mellitus</subject><subject>Endocrinology</subject><subject>Fatty liver</subject><subject>Hemoglobin</subject><subject>Liver</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Metabolic Diseases</subject><subject>Multiple regression analysis</subject><subject>Original</subject><subject>Original Article</subject><subject>Spleen</subject><subject>Steatosis</subject><subject>Tomography</subject><subject>Transaminase</subject><issn>2190-1678</issn><issn>2190-1686</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><recordid>eNp1Uk2L3DAMDaWlu0z3B_RSDL30ktZ2Jk5yKZSlnyz0sj0bxVFmvDh2ajtT0h_X31YNsx22hRqBhPX0JKFXFM8Ffy04b94kUVVbXnKhSl5xWa6PikspOl4K1arH57hpL4qrlO44vW0neKOeFhcVV7yqZH1Z_LrdI8NxRJMTCyOzc4Sds6MLP61nwbNMeWcPGMscyjQ7RM8gZ_QLZEv5eHQMEllCsoH1KzNhmpdMcQ5T2EWY9ysDPxz5wIG3HlmO4BNM1kOiBnhAlxh1_AIzeKSvmXjR01A_bN6zvM7IJBss9JgxsQmds3lJz4onI7iEV_d-U3z78P72-lN58_Xj5-t3N6WpuzqXFSquRN1II6BFse1kP4rt0GI7qlpAjbxXTd0ZaaQaexTt0ElojOKtkh2Bqk3x9sQ7L_2Eg6HJIjg9RztBXHUAq__OeLvXu3DQSsptV0sieHVPEMP3BVPWk02GtqBtw5K0FKriNBidZVO8_Ad6F5boaT1NJxWN6mrBCSVOKBNDShHH8zCC66NA9EkgmgSijwLRK9W8eLjFueKPHAggT4BEKb_D-KD1f1l_A6cny3U</recordid><startdate>20170601</startdate><enddate>20170601</enddate><creator>Bando, Yukihiro</creator><creator>Ogawa, Ayumi</creator><creator>Ishikura, Kazuhide</creator><creator>Kanehara, Hideo</creator><creator>Hisada, Azusa</creator><creator>Notumata, Kazuo</creator><creator>Okafuji, Kazuhiro</creator><creator>Toya, Daisyu</creator><general>Springer Japan</general><general>Springer Nature B.V</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20170601</creationdate><title>The effects of ipragliflozin on the liver-to-spleen attenuation ratio as assessed by computed tomography and on alanine transaminase levels in Japanese patients with type 2 diabetes mellitus</title><author>Bando, Yukihiro ; Ogawa, Ayumi ; Ishikura, Kazuhide ; Kanehara, Hideo ; Hisada, Azusa ; Notumata, Kazuo ; Okafuji, Kazuhiro ; Toya, Daisyu</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c595t-3e6061572c1a8e1492bf14d8e8f651a5e0b6759c2c26fbe18d92a7c608629e8f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Age</topic><topic>Alanine</topic><topic>Alanine transaminase</topic><topic>Body mass</topic><topic>Body mass index</topic><topic>Computed tomography</topic><topic>Diabetes</topic><topic>Diabetes mellitus</topic><topic>Endocrinology</topic><topic>Fatty liver</topic><topic>Hemoglobin</topic><topic>Liver</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Metabolic Diseases</topic><topic>Multiple regression analysis</topic><topic>Original</topic><topic>Original Article</topic><topic>Spleen</topic><topic>Steatosis</topic><topic>Tomography</topic><topic>Transaminase</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bando, Yukihiro</creatorcontrib><creatorcontrib>Ogawa, Ayumi</creatorcontrib><creatorcontrib>Ishikura, Kazuhide</creatorcontrib><creatorcontrib>Kanehara, Hideo</creatorcontrib><creatorcontrib>Hisada, Azusa</creatorcontrib><creatorcontrib>Notumata, Kazuo</creatorcontrib><creatorcontrib>Okafuji, Kazuhiro</creatorcontrib><creatorcontrib>Toya, Daisyu</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Diabetology international</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bando, Yukihiro</au><au>Ogawa, Ayumi</au><au>Ishikura, Kazuhide</au><au>Kanehara, Hideo</au><au>Hisada, Azusa</au><au>Notumata, Kazuo</au><au>Okafuji, Kazuhiro</au><au>Toya, Daisyu</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The effects of ipragliflozin on the liver-to-spleen attenuation ratio as assessed by computed tomography and on alanine transaminase levels in Japanese patients with type 2 diabetes mellitus</atitle><jtitle>Diabetology international</jtitle><stitle>Diabetol Int</stitle><addtitle>Diabetol Int</addtitle><date>2017-06-01</date><risdate>2017</risdate><volume>8</volume><issue>2</issue><spage>218</spage><epage>227</epage><pages>218-227</pages><issn>2190-1678</issn><eissn>2190-1686</eissn><abstract><![CDATA[We assessed the effects of a 12-week ipragliflozin treatment on the liver-to-spleen attenuation ratio (
L
/
S
ratio) using computed tomography and on alanine transaminase (ALT) levels in Japanese patients with type 2 diabetes mellitus (T2DM). Sixty-two patients with T2DM [age, 56 ± 8 years; hemoglobin A1c (HbA1c) levels, 8.1 ± 0.9%; body mass index (BMI), 27.5 ± 3.3 kg/m
2
] were randomly assigned in a 2:1 ratio to receive ipragliflozin (50 mg/day; ipragliflozin group;
n
= 40) or continued treatment (control group;
n
= 22) for 12 weeks. The primary endpoints were changes in ALT levels; the secondary endpoints included changes in the
L
/
S
ratio and in the visceral fat area (VFA) and subcutaneous fat area (SFA) before and after 12 weeks of the treatment as assessed by computed tomography. ALT levels (−12.45 vs. +5.82 IU/l,
P
< 0.001),
L
/
S
ratio (+0.07 vs. −0.08,
P
< 0.001), SFA (−5.8 vs. +13.3 cm
2
,
P
< 0.05), and VFA (+1.4 vs. +20.4 cm
2
,
P
< 0.05) significantly changed from baseline in the ipragliflozin group compared with the values in the control group. Multiple regression analysis among all subjects revealed that the independent factor contributing to the %ΔALT and %Δ
L
/
C
ratio was treatment group alone (ipragliflozin group = 1; control group = 0;
β
coefficient = −32.08,
P
< 0.001 and
β
coefficient = 19.98,
P
< 0.05, respectively). Thus, ipragliflozin may lower ALT levels associated with increased
L
/
S
ratios, indicating its potential therapeutic efficacy in T2DM-associated hepatic steatosis.]]></abstract><cop>Tokyo</cop><pub>Springer Japan</pub><pmid>30603325</pmid><doi>10.1007/s13340-016-0302-y</doi><tpages>10</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2190-1678 |
| ispartof | Diabetology international, 2017-06, Vol.8 (2), p.218-227 |
| issn | 2190-1678 2190-1686 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6224952 |
| source | PubMed (Medline); Springer Nature |
| subjects | Age Alanine Alanine transaminase Body mass Body mass index Computed tomography Diabetes Diabetes mellitus Endocrinology Fatty liver Hemoglobin Liver Medicine Medicine & Public Health Metabolic Diseases Multiple regression analysis Original Original Article Spleen Steatosis Tomography Transaminase |
| title | The effects of ipragliflozin on the liver-to-spleen attenuation ratio as assessed by computed tomography and on alanine transaminase levels in Japanese patients with type 2 diabetes mellitus |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T03%3A05%3A08IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20effects%20of%20ipragliflozin%20on%20the%20liver-to-spleen%20attenuation%20ratio%20as%20assessed%20by%20computed%20tomography%20and%20on%20alanine%20transaminase%20levels%20in%20Japanese%20patients%20with%20type%202%20diabetes%20mellitus&rft.jtitle=Diabetology%20international&rft.au=Bando,%20Yukihiro&rft.date=2017-06-01&rft.volume=8&rft.issue=2&rft.spage=218&rft.epage=227&rft.pages=218-227&rft.issn=2190-1678&rft.eissn=2190-1686&rft_id=info:doi/10.1007/s13340-016-0302-y&rft_dat=%3Cproquest_pubme%3E2163014903%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c595t-3e6061572c1a8e1492bf14d8e8f651a5e0b6759c2c26fbe18d92a7c608629e8f3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1901769510&rft_id=info:pmid/30603325&rfr_iscdi=true |